Rhythm Pharmaceuticals, Inc. has announced a public offering of $150 million in common stock. All securities in this offering will be offered by Rhythm, and the company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in shares. The offering is being conducted under a shelf registration statement on Form S-3, which became effective in March 2023. The offering's final terms, including size and conditions, will be disclosed in a prospectus supplement filed with the SEC. Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities are serving as joint book-running managers, while Canaccord Genuity and Citizens Capital Markets are acting as lead managers. Completion of the offering is subject to market conditions and other customary closing conditions.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。